Concepedia

Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points

L. Lee, L. Wang, Michael Crump

Annals of Oncology · 2011 · 41 citations · 67 references

DOIFull text

Open access

Concepts

References

67

CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

Bertrand Coiffier, Éric Lepage, Josette Brière et al. · New England Journal of Medicine · 2002 · 5.6K citations · Full text

, , +9

Revised Response Criteria for Malignant Lymphoma

Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text

, , +15

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Lorenz Trümper, Anders Österborg et al. · The Lancet Oncology · 2006 · 2.1K citations

, , +11

Surrogate endpoints in clinical trials: Definition and operational criteria

Ross L. Prentice · Statistics in Medicine · 1989 · 2K citations

, , +14

Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

Thomas M. Habermann, Edie Weller, Vicki A. Morrison et al. · Journal of Clinical Oncology · 2006 · 1.4K citations · Full text

, , +12